FDA 483 - Cdymax (India) Pharma Private Limited - April 21, 2025

The FDA conducted an inspection of Cydmax (India) Pharma Private Limited, an API manufacturer located in Bangalore, India, from April 21 to April 25, 2025. The inspection revealed significant issues with the company's quality management practices, particularly concerning the handling of out-of-specification (OOS) results. The primary violation identified was the inadequate investigation of unexplained discrepancies and failures in batch specifications. The firm's Quality Unit often failed to conduct comprehensive investigations to determine root causes and did not document corrective and preventive actions (CAPAs) effectively.

Specific observations included the misclassification of OOS results as laboratory incidents, leading to data invalidation without proper root cause analysis. The company frequently performed reanalysis until achieving desirable results, which were then reported without addressing the underlying issues. For instance, in several cases, initial OOS results were attributed to sample contamination or equipment errors without sufficient justification or effective CAPAs.

The FDA requires Cydmax to enhance its investigation procedures, ensuring all potential root causes are identified and addressed comprehensively. The firm must also improve its documentation practices and ensure CAPAs are effective and not repetitive. The FDA emphasized the need for Cydmax to align its practices with regulatory standards to ensure product quality and compliance.